Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Foresite Capital Fund III, L.P. and Cymabay Therapeutics Inc. (CBAY)

Cymabay Therapeutics Inc. (NASDAQ:CBAY): Jim Tananbaum’s Foresite Capital Fund III, L.P. filed an amended 13D.

You can check out Foresite Capital’s latest holdings and filings here.

Please follow Foresite Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Foresite Capital or update its stock holdings.

Jim Tananbaum
Jim Tananbaum
Foresite Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Foresite Capital Fund III 600,000 600,000 600,000 1.4%
Foresite Capital Management III 600,000 600,000 600,000 1.4%
Foresite Capital Fund IV 2,091,792 2,091,792 2,091,792 4.7%
Foresite Capital Management IV 2,091,792 2,091,792 2,091,792 4.7%
James Tananbaum ( Tananbaum ) 2,691,792 2,691,792 2,691,792 6.2%

Page 1 of 11 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. ___________)*

CymaBay Therapeutics,
Inc.

(Name of
Issuer)

Common Stock, par value $0.0001

(Title of
Class of Securities)

23257D103

(CUSIP Number)

November 1, 2017

(Date of
Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

(Continued on following pages)

Page 1 of 11

Exhibit Index on Page 10

Follow Cymabay Therapeutics Inc. (NASDAQ:CBAY)
Trade (NASDAQ:CBAY) Now!
Loading...